"We believe, together with the other vaccine developers, in the next 9 to 12 months, that there will be more than enough vaccine produced and there is absolutely no need for waiving patents,” he said. The Mainz-based company said its revenues included over 1.75 billion euros in gross profits from vaccine sales in Pfizer's territories, and almost 200 million from sales to customers in its region. Based on current orders for some 1.8 billion doses, it expects full-year revenues of 12.4 billion euros in 2021. Early last year as the pandemic began, BioNTech pivoted from researching treatments for cancer to developing a vaccine against COVID-19. Like its rival Moderna, the company's vaccine uses mRNA technology to prime the body's immune system to attack the virus.

Source: ABC News May 10, 2021 12:10 UTC